Skip to main content
Signal8

U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

$GILDPress releaseJun 15, 2026, 4:34 PM ETRead the release

Gilead Sciences announced that the FDA has accepted its supplemental New Drug Application for once-weekly oral Yeztugo (lenacapavir) for HIV prevention. The FDA assigned a Prescription Drug User Fee Act action date of February 2, 2027, with the submission supported by data from the PURPOSE 1 and PURPOSE 2 trials.

Key figures

Drug Name
Yeztugo (lenacapavir)
Dosage
300-mg tablet
Frequency
once-weekly
Indication
pre-exposure prophylaxis (PrEP)
Pdufa date
February 2, 2027

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.